{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations are associated with reduced interaction with and phosphorylation of Akt1, suggesting a mechanism for neurodegeneration in Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper describes a mechanism where LRRK2 mutations lead to reduced Akt1 phosphorylation, which is linked to neurodegeneration."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase assay and pull-down assays were used to demonstrate LRRK2's interaction and phosphorylation of Akt1.",
          "judgment": "Yes",
          "reasoning": "The assays used are standard for studying protein interactions and phosphorylation, relevant to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The assays included controls and were performed with replicates.",
          "judgment": "Yes",
          "reasoning": "The paper describes the use of controls and replicates, supporting the validity of the assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study used known pathogenic variants as controls.",
          "judgment": "Yes",
          "reasoning": "The inclusion of known pathogenic variants as controls strengthens the evidence.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Statistical analyses were not detailed enough for OddsPath calculation.",
          "judgment": "No",
          "reasoning": "The paper does not provide sufficient statistical analysis for OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used three known pathogenic variants as controls.",
          "judgment": "10 or less",
          "reasoning": "The number of control variants is less than 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R1441C variant in LRRK2 shows reduced phosphorylation activity towards Akt1, suggesting a pathogenic role, but the evidence is limited to supporting strength due to the number of controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations are associated with reduced interaction with and phosphorylation of Akt1, suggesting a mechanism for neurodegeneration in Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper describes a mechanism where LRRK2 mutations lead to reduced Akt1 phosphorylation, which is linked to neurodegeneration."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase assay and pull-down assays were used to demonstrate LRRK2's interaction and phosphorylation of Akt1.",
          "judgment": "Yes",
          "reasoning": "The assays used are standard for studying protein interactions and phosphorylation, relevant to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The assays included controls and were performed with replicates.",
          "judgment": "Yes",
          "reasoning": "The paper describes the use of controls and replicates, supporting the validity of the assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study used known pathogenic variants as controls.",
          "judgment": "Yes",
          "reasoning": "The inclusion of known pathogenic variants as controls strengthens the evidence.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Statistical analyses were not detailed enough for OddsPath calculation.",
          "judgment": "No",
          "reasoning": "The paper does not provide sufficient statistical analysis for OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used three known pathogenic variants as controls.",
          "judgment": "10 or less",
          "reasoning": "The number of control variants is less than 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The G2019S variant in LRRK2 shows reduced phosphorylation activity towards Akt1, suggesting a pathogenic role, but the evidence is limited to supporting strength due to the number of controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations are associated with reduced interaction with and phosphorylation of Akt1, suggesting a mechanism for neurodegeneration in Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper describes a mechanism where LRRK2 mutations lead to reduced Akt1 phosphorylation, which is linked to neurodegeneration."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase assay and pull-down assays were used to demonstrate LRRK2's interaction and phosphorylation of Akt1.",
          "judgment": "Yes",
          "reasoning": "The assays used are standard for studying protein interactions and phosphorylation, relevant to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The assays included controls and were performed with replicates.",
          "judgment": "Yes",
          "reasoning": "The paper describes the use of controls and replicates, supporting the validity of the assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study used known pathogenic variants as controls.",
          "judgment": "Yes",
          "reasoning": "The inclusion of known pathogenic variants as controls strengthens the evidence.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Statistical analyses were not detailed enough for OddsPath calculation.",
          "judgment": "No",
          "reasoning": "The paper does not provide sufficient statistical analysis for OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used three known pathogenic variants as controls.",
          "judgment": "10 or less",
          "reasoning": "The number of control variants is less than 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The I2020T variant in LRRK2 shows reduced phosphorylation activity towards Akt1, suggesting a pathogenic role, but the evidence is limited to supporting strength due to the number of controls."
    }
  ]
}
